The appointment of Dr Ralf Rosskamp as Chief Medical Officer strengthens the group’s management team as it continues to progress with its two development programmes, utrophin modulation for Duchenne Muscular Dystrophy (DMD) and SMT 19969 for C. difficile infection. We were extremely encouraged to note that SMT C1100 met its primary objective in its Phase Ib modified diet clinical trial last month and will commence a Phase II open label trial in Q4 2015. There is currently no cure for DMD, a fata ....
